What are the applicable populations for Baloxavir marboxil (Xofluza)?

What are the applicable populations for Baloxavir marboxil (Xofluza)?

In addition to treating existing flu symptoms, Baloxavir marboxil (Xofluza) is also approved for post-exposure prophylaxis. This means that if someone in your household has been diagnosed with the flu, or if you have had close contact with a flu patient, taking a single dose of Baloxavir marboxil (Xofluza) can help prevent you from actually getting the flu. Clinical trial data show that, after exposure to flu patients, Baloxavir marboxil (Xofluza) reduces the risk of infection by 87% in people aged 5 and older, compared with a placebo group. This is particularly important for interrupting household transmission, especially during peak flu season. It should be emphasized that prophylactic use also requires rapid action because the window for prevention after virus exposure is short. If you or a family member (aged 5 and older) has had definite exposure to a flu patient, consult a doctor as soon as possible about whether Baloxavir marboxil (Xofluza) is suitable for post-exposure prophylaxis.

Who is at high risk for influenza complications?

According to the CDC, certain people are more likely to develop serious complications from the flu, even requiring hospitalization. These high-risk groups include: older adults (usually defined as 65 years and older), pregnant women, and individuals with certain chronic underlying conditions. Underlying conditions cover a wide range, such as asthma, diabetes, heart disease, chronic lung disease, kidney disease, liver disease, and those who are immunocompromised due to illness or medication. It is worth noting that infants and young children (especially those under 5 years old, and particularly children younger than 2) are also a high-risk group. For these high-risk individuals, early use of prescription antiviral drugs (such as Baloxavir marboxil (Xofluza)) is especially important. If you or a family member falls into one of the above categories, seek medical help within 48 hours of developing flu symptoms or after exposure to a patient, and proactively ask whether a single dose of Baloxavir marboxil (Xofluza) is appropriate for treatment.

Can I take Baloxavir marboxil (Xofluza) after being vaccinated?

Many patients ask: If I have already received the flu vaccine this year but still get the flu, can I still take Baloxavir marboxil (Xofluza)? The answer is yes. The flu vaccine works by stimulating the body to produce antibodies to prevent infection, but the vaccine's protective effect is not 100%. Additionally, the circulating flu virus strains each year may not exactly match the vaccine formulation, or the body may not have developed sufficient immunity by the time of virus exposure. In these cases, you can still get the flu. Once ill, using Baloxavir marboxil (Xofluza) for treatment is completely safe and effective. It works through a different mechanism from the vaccine and does not interfere with it. However, one timing point to note: if you need to receive a live flu vaccine after taking Baloxavir marboxil (Xofluza), be sure to inform your healthcare provider first, so they can assess the timing. In summary, vaccination is a line of defense, and Baloxavir marboxil (Xofluza) is a backup weapon; the two can work together at different stages to protect your health.